Take part in research

Share

Aa-+

Clinical studies

dal-GenE

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial

Dal-GenE is a worldwide phase 3 study. The study aims to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in participants having recently been hospitalized for an acute coronary syndrome (heart attack or ischemia) and with the AA genetic variant in the ADCY9 gene.

Principal Investigator: Dr. Jean C. Grégoire

Study start date: March 15th, 2016.

Planned duration of participation in the study: From 2.5 to 5 years

We are seeking:

  • Men or Women ≥ 45 years; 
  • Participants having been hospitalized for an acute coronary syndrome within 4 to 12 weeks prior enrollment in the study;
  • Participants with the AA variant in the ADCY9 gene;
  • Participants who are not suffering from heart failure or liver disease.

Your participation entails:

During the study, participants will need to take 2 tablets of the study medication (dalcetrapib or placebo) once a day. They will be asked to come to the clinic every 6 months for a follow-up visit for approximately 2.5 to 5 years. Blood samples will be collected at the screening visit (to confirm the genetic profile inclusion criteria), at the randomization visit, as well as the 6 months visit. 

For additional information or to participate in this study, please contact :

Colette Morin at 514-376-3330 ext.3337


BRAIN-AF

The BRAIN-AF clinical study is conducted by a team of specialists and researchers from the Montreal Heart Institute (MHI) in collaboration with the Canadiean Stroke Prevention Intervention Network, the phamaceutical company Bayer, the Montreal Health Innovations Coordinating Center (MHICC) and the MHI Foundation.

The study, which is a world first, aims to demonstrate that taking low dose of rivaroxaban, an anticoagulant, could decrease the risk of developing cognitive impairment, transient ischemic attack or stroke in patients with atrial fibrillation. This clinical study was announced on november 19th 2015.

You whish to learn more about this study? View our French Virtual Conference. HERE

Participate in this clinical study:

The MHI BRAIN-AF team is currently seeking participants for this study. Patients under 60 years of age with atrial fibrillation are potentially admissible for this clinical study. If you would like to get further information or if you are interested in participating in this study, please contact:

Research coordinator :  Diane David
Telephone :    514-376-3330 poste 2884
E-mail: diane.david@icm-mhi.org

What does BRAIN-AF stand for?

BRAIN-AF is the acronym for Blended Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation.

COLCOT

Colchicine Cardiovascular Outcomes Trial - COLCOT

COLCOT clinical trial is an international phase 3 study. This study will evaluate the impact of colchicine, a well-known anti-inflammatory drug used for hundreds of years for various conditions, on the reduction of cardiovascular events recurrence in patient recently diagnosed with myocardial infarction.

Principal Investigator: Dr Philippe L.-L'Allier

Participate in this clinical study:

We are seeking:

  • Men or women ≥18 years old.
  • Subjects who have suffered a heart attack within the last 30 days.
  • Subjects who have not undergone a coronary artery bypass graft in the last 3 years.
  • Subjects who are not suffering from inflammatory bowel diseases (Crohn’s disease or ulcerative colitis) or chronic diarrhea.
  • Subjects who are not currently taking colchicine for another indication.

Your participation entails:

For the duration of the trial, subjects will take the study medication (colchicine or placebo), one tablet once a day. Furthermore, they will have to attend 2 visits per year at the site. Subjects will also have a phone visit twice per year in between their in-person visit.

  • Study start date: October 15th 2015
  • Planned duration of participation in the study: Minimum of 2 years

Additional information:
If you would like to get further information or if you are interested in participating in this study, please contact:

Research coordinator:  Patricia Blaise
Telephone: 514-376-3330, extension 2740

dal-GenE

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial

Dal-GenE is a worldwide phase 3 study. The study aims to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in participants having recently been hospitalized for an acute coronary syndrome (heart attack or ischemia) and with the AA genetic variant in the ADCY9 gene.

Principal Investigator: Dr. Jean C. Grégoire

Study start date: March 15th, 2016.

Planned duration of participation in the study: From 2.5 to 5 years

We are seeking:

  • Men or Women ≥ 45 years; 
  • Participants having been hospitalized for an acute coronary syndrome within 4 to 12 weeks prior enrollment in the study;
  • Participants with the AA variant in the ADCY9 gene;
  • Participants who are not suffering from heart failure or liver disease.

Your participation entails:

During the study, participants will need to take 2 tablets of the study medication (dalcetrapib or placebo) once a day. They will be asked to come to the clinic every 6 months for a follow-up visit for approximately 2.5 to 5 years. Blood samples will be collected at the screening visit (to confirm the genetic profile inclusion criteria), at the randomization visit, as well as the 6 months visit. 

For additional information or to participate in this study, please contact :

Colette Morin at 514-376-3330 ext.3337


BRAIN-AF

The BRAIN-AF clinical study is conducted by a team of specialists and researchers from the Montreal Heart Institute (MHI) in collaboration with the Canadiean Stroke Prevention Intervention Network, the phamaceutical company Bayer, the Montreal Health Innovations Coordinating Center (MHICC) and the MHI Foundation.

The study, which is a world first, aims to demonstrate that taking low dose of rivaroxaban, an anticoagulant, could decrease the risk of developing cognitive impairment, transient ischemic attack or stroke in patients with atrial fibrillation. This clinical study was announced on november 19th 2015.

You whish to learn more about this study? View our French Virtual Conference. HERE

Participate in this clinical study:

The MHI BRAIN-AF team is currently seeking participants for this study. Patients under 60 years of age with atrial fibrillation are potentially admissible for this clinical study. If you would like to get further information or if you are interested in participating in this study, please contact:

Research coordinator :  Diane David
Telephone :    514-376-3330 poste 2884
E-mail: diane.david@icm-mhi.org

What does BRAIN-AF stand for?

BRAIN-AF is the acronym for Blended Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation.

COLCOT

Colchicine Cardiovascular Outcomes Trial - COLCOT

COLCOT clinical trial is an international phase 3 study. This study will evaluate the impact of colchicine, a well-known anti-inflammatory drug used for hundreds of years for various conditions, on the reduction of cardiovascular events recurrence in patient recently diagnosed with myocardial infarction.

Principal Investigator: Dr Philippe L.-L'Allier

Participate in this clinical study:

We are seeking:

  • Men or women ≥18 years old.
  • Subjects who have suffered a heart attack within the last 30 days.
  • Subjects who have not undergone a coronary artery bypass graft in the last 3 years.
  • Subjects who are not suffering from inflammatory bowel diseases (Crohn’s disease or ulcerative colitis) or chronic diarrhea.
  • Subjects who are not currently taking colchicine for another indication.

Your participation entails:

For the duration of the trial, subjects will take the study medication (colchicine or placebo), one tablet once a day. Furthermore, they will have to attend 2 visits per year at the site. Subjects will also have a phone visit twice per year in between their in-person visit.

  • Study start date: October 15th 2015
  • Planned duration of participation in the study: Minimum of 2 years

Additional information:
If you would like to get further information or if you are interested in participating in this study, please contact:

Research coordinator:  Patricia Blaise
Telephone: 514-376-3330, extension 2740